Journal of Nuclear Science, Engineering and Technology (JONSAT)
In cooperation with the Iranian Nuclear Society

Production and Labeling of Rhenium-186 and 188 via HEDP Using Natural Rhenium and it’s Biodistribution in Rats

Document Type : Research Paper

Authors

L Moghaddam-Banaem
S Setayeshi
M Ghannadi
S.J Ahmadi
R Gholipour
M.A Firouz zareh
S.M Mazidi
S.H Mirfalah
Abstract
In this project, production of radioactive rhenium for medical application by the Tehran Research Reactor, using natural rhenium along with labeling Rhenium by hydroxy ethiliden diphosphonate(HEDP) was investigated. After the production of Re-HEDP, its biodistribution in rats was also evaluated. To obtain the radioactive isotopes, natural rhenium with %99.9 purity, manufactured by Merck, was irradiated by the Tehran Research Reactor. Natural rhenium consists of two isotopes, Re-185 and Re-187, so irradiation the target with neutron in the reactor eventuates in two radioisotopes,186Re and 188Re. This research was performed in three phases. At the first phase, rhenium was irradiated in various irradiation boxes. The best result was 470mCi/mg after 5 days of irradiation. The chemical process includes oxidation of Re which in the presence of water results in formation of perhenic acid. Afterward, labeling of HEDP by means of Re is performed. All the process was performed in Lead Cell. Gamma spectroscopy and Thin Layer Chromatography were used for radionuclide and radiochemical purity, respectively. Re-HEDP was injected in rats and the biodistribution in different organs were studied by means of gamma spectroscopy. The results of the gamma spectroscopy approved the radionuclide purity. Labeling via HEDP resulted in %97.57 radiochemical purity. Biodistribution in rats showed (1.007 %ID/g 4h P.I), (0.89%ID/g 24h P.I) and (0.58 %ID/g 48h P.I) for bone and was the maximum percent of the absorbed dose rate.

Highlights

  1. 1.    K. Hashimoto, K. Yoshihara, “Rhenium Complexes Labeled with 186,188Re for Nuclear Medicine,” Topics in current Chemistry, V. 176 (1996).

 

  1. 2.    K. Liepe, R. Hliscs, J. Kropp, R. Runge, F.F. Knapp, W.G. Franke, “Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases,” The journal of Nuclear Medicine, V.44, No. 6, June (2003).

 

  1. 3.    J. Gaudiano, E. Savio, A. Paolino, “Relationship of Bone Uptake to radiation Doses in Bone Pain Treatment with 188Re-HEDP,” IAEA-CN-96/67P (1996).

 

  1. 4.    F.F. Knapp, J. Pinkert, J. Kropp, W.Y. Lin, S.Y. Wang, “Rhenium Radioisotopes for Therapeutic Radiopharmaceuticals Development,” IAEA-TECDOC, 59-66,  January (1999).

 

  1. 5.    DCE Ng, MBBS, MRCP, FAMS, “Radioimmunotherapy: Brief Overview,” Biomedical Imaging and Intervention Journal, V.2(3) (2006).

 

  1. 6.    V.J. Lewington, “Cancer Therapy Using Bone-Seeking Isotopes,” Phys. Med. Biol. V.41,  2027-2042 (1996).

 

  1. 7.    Neeta Pandit-Taskar, M. Batraki, C.H. Divgi, “Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseos Matastases,” Journal of Nuclear Medicine, V. 45, No. 8, August (2004).

 

  1. 8.    K. Ogawa, T. Mukari, Y. Arano, A. Otaka, M. Ueda, T. Uehara, Y. Magata, K. Hashimoto, H. Saji, “Rhenium-186-Monoaminemonoamidedithiol-Conjugated Bisphosphonate Derivative For Bone Pain Palliation,” Nuclear medicine and Biology Journal, V. 33, 513-520 (2006).

 

  1. 9.    Lin Uei-Tyng, Chu Chein-Hau, Hsieh Bor-Tsung, Hwang Wen-Song, “Dose evaluation and measurement of the 188Re liquid-filled balloon in intravascular brachytherapy,” Applied Radiation and Isotopes , V.61, 1323-1333 (2004).

 

  1. 10.              L. Solin, V.A. Jakovlev, I.E. Alekseev, V.V. Lazarev, “Cyclotron Yields of Rhenium-186,” Medimond, 131-136 (2005).

 

  1. 11.              R.A. Kuznetsov, C. Daming, A.N. Pakhomov, S.I. Klimov, Y. Honwei, C. Benzhu, “188W/188Re Generator Of 1 Ci Activity,” Medimond, F425R0025, 55-62 (2005).

 

  1. 12.              G. Pfennig, H. Klewe-Nebenius, W. Seelmann-Eggebert, “Chart of the nuclides,” Markdienste Haberbeck GmbH, ISBN 3-921879-18-3 (1998).

 

  1. 13.              R. Sayare, M. Ghannadi Maragheh, M. Shamsaie, “Theoretical calculations for the production of 99Mo using natural uranium in Iran,” Annals of Nuclear Energy, V.30, 883-895 (2003).

 

  1. 14.              IAEA-TECDOC-1340 , “Manual for reactor produced radioisotopes,” January (2003).

 

  1. 15.              H.R. Maxon, L.E. Schroder, L.C. Washburn, S.R. Thomas, R.C. Samaratunga, D. Biniakiewicz, J.S. Moulton, D. Cummings, G. Ehrhardt, V. Morris, “Rhenium-188(Sn)HEDP for Treatment of Osseous Metastases,” The Journal of Nuclear Medicine, V. 39, No. 4 (1998).

 

  1. 16.              W.Y. Lin, C.P. Ling, S.J. Yeh, B.T. Hsieh, Z.T. Tsai, G. Ting, T.C. Yen, S.J. Wang, F.F. Knapp Jr, M.G. Stabin, “Rhenium-188 HEDP: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases,” European journal of Nuclear Medicine and molecular Imaging,V. 24 No. 6, June (1997).

 

  1. 17.              G.S. Limouris, S.K. Skukla, “Gastric uptake during Re-186 HEDP bone scintigraphy,” Anticancer-Res. V.17, No. 3B, 1779-1781 (1997).

Keywords

Radiopharmaceutical
Rhenium 186 and Rhenium 188
Lebeling
HEDP (Hydroxy Ethilidene Diphoshponate)
Tissus Distribution
  1. 1.    K. Hashimoto, K. Yoshihara, “Rhenium Complexes Labeled with 186,188Re for Nuclear Medicine,” Topics in current Chemistry, V. 176 (1996).

 

  1. 2.    K. Liepe, R. Hliscs, J. Kropp, R. Runge, F.F. Knapp, W.G. Franke, “Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases,” The journal of Nuclear Medicine, V.44, No. 6, June (2003).

 

  1. 3.    J. Gaudiano, E. Savio, A. Paolino, “Relationship of Bone Uptake to radiation Doses in Bone Pain Treatment with 188Re-HEDP,” IAEA-CN-96/67P (1996).

 

  1. 4.    F.F. Knapp, J. Pinkert, J. Kropp, W.Y. Lin, S.Y. Wang, “Rhenium Radioisotopes for Therapeutic Radiopharmaceuticals Development,” IAEA-TECDOC, 59-66,  January (1999).

 

  1. 5.    DCE Ng, MBBS, MRCP, FAMS, “Radioimmunotherapy: Brief Overview,” Biomedical Imaging and Intervention Journal, V.2(3) (2006).

 

  1. 6.    V.J. Lewington, “Cancer Therapy Using Bone-Seeking Isotopes,” Phys. Med. Biol. V.41,  2027-2042 (1996).

 

  1. 7.    Neeta Pandit-Taskar, M. Batraki, C.H. Divgi, “Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseos Matastases,” Journal of Nuclear Medicine, V. 45, No. 8, August (2004).

 

  1. 8.    K. Ogawa, T. Mukari, Y. Arano, A. Otaka, M. Ueda, T. Uehara, Y. Magata, K. Hashimoto, H. Saji, “Rhenium-186-Monoaminemonoamidedithiol-Conjugated Bisphosphonate Derivative For Bone Pain Palliation,” Nuclear medicine and Biology Journal, V. 33, 513-520 (2006).

 

  1. 9.    Lin Uei-Tyng, Chu Chein-Hau, Hsieh Bor-Tsung, Hwang Wen-Song, “Dose evaluation and measurement of the 188Re liquid-filled balloon in intravascular brachytherapy,” Applied Radiation and Isotopes , V.61, 1323-1333 (2004).

 

  1. 10.              L. Solin, V.A. Jakovlev, I.E. Alekseev, V.V. Lazarev, “Cyclotron Yields of Rhenium-186,” Medimond, 131-136 (2005).

 

  1. 11.              R.A. Kuznetsov, C. Daming, A.N. Pakhomov, S.I. Klimov, Y. Honwei, C. Benzhu, “188W/188Re Generator Of 1 Ci Activity,” Medimond, F425R0025, 55-62 (2005).

 

  1. 12.              G. Pfennig, H. Klewe-Nebenius, W. Seelmann-Eggebert, “Chart of the nuclides,” Markdienste Haberbeck GmbH, ISBN 3-921879-18-3 (1998).

 

  1. 13.              R. Sayare, M. Ghannadi Maragheh, M. Shamsaie, “Theoretical calculations for the production of 99Mo using natural uranium in Iran,” Annals of Nuclear Energy, V.30, 883-895 (2003).

 

  1. 14.              IAEA-TECDOC-1340 , “Manual for reactor produced radioisotopes,” January (2003).

 

  1. 15.              H.R. Maxon, L.E. Schroder, L.C. Washburn, S.R. Thomas, R.C. Samaratunga, D. Biniakiewicz, J.S. Moulton, D. Cummings, G. Ehrhardt, V. Morris, “Rhenium-188(Sn)HEDP for Treatment of Osseous Metastases,” The Journal of Nuclear Medicine, V. 39, No. 4 (1998).

 

  1. 16.              W.Y. Lin, C.P. Ling, S.J. Yeh, B.T. Hsieh, Z.T. Tsai, G. Ting, T.C. Yen, S.J. Wang, F.F. Knapp Jr, M.G. Stabin, “Rhenium-188 HEDP: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases,” European journal of Nuclear Medicine and molecular Imaging,V. 24 No. 6, June (1997).

 

  1. 17.              G.S. Limouris, S.K. Skukla, “Gastric uptake during Re-186 HEDP bone scintigraphy,” Anticancer-Res. V.17, No. 3B, 1779-1781 (1997).

Home